Tirzepatide max dosage: reaching 15mg and what to expect

Step 1: why treatment starts at 2.5mg, not higher

Every tirzepatide course begins at 2.5mg. That isn't a therapeutic dose in the weight-loss sense; its purpose is to settle the GI system before stronger concentrations arrive. Nausea, vomiting and loose stools are the most common early side effects, and the graduated start meaningfully reduces their severity for most people. The NHS tirzepatide medicines page is clear that this early phase is about tolerability, not results.

After around four weeks on 2.5mg, a prescriber can increase to 5mg, and so on through 7.5mg, 10mg, 12.5mg, up to the 15mg maximum. Four weeks at each level is the standard minimum; rushing the schedule tends to amplify side effects without adding benefit. Some patients take longer between increases, and that is clinically normal.

A practical note: each pen lives in the fridge door alongside everything else that needs to stay cold. If you travel, the SmPC sets out a limited window for room-temperature storage, check the Patient Information Leaflet for the exact figure, because that detail matters and it isn't something to guess at.

Step 2: intermediate doses are not stepping stones to skip

There is a temptation to view 5mg, 7.5mg and 10mg as inconveniences on the way to 15mg. The evidence does not support that view. In the SURMOUNT-1 trial, participants on lower maintenance doses still achieved clinically meaningful weight reduction. The tirzepatide dosing guide covers this in detail, but the short version is: the dose that suits you is the highest one you tolerate well, which may be 10mg or 12.5mg rather than the ceiling.

Prescribers at nume review your progress before each increase. That review considers how you are tolerating the current dose, whether weight loss is continuing, and whether any new symptoms need attention. It is never automatic. Patients who experience persistent nausea or other GI symptoms at a given strength may stay there longer, or the prescriber may explore whether a different approach fits better.

If you are curious about what the move from a specific strength actually involves, the 5mg dose page explains that transition in practical terms, and our guide to the tirzepatide 10mg dosage walks through what to expect when you reach that stage of the schedule.

Step 3: what happens at 15mg, and what the trial data actually shows

At the maximum dose, tirzepatide's dual GIP and GLP-1 receptor activity is at its strongest. In SURMOUNT-1 (which enrolled 2,539 adults with obesity) participants on 15mg achieved an average body-weight reduction of around 20–21% over 72 weeks, with some analyses reaching approximately 22.5%. Those are averages from a clinical trial, not guarantees; individual results vary, and they were achieved alongside a reduced-calorie diet and increased activity.

NICE's recommendation (TA1026) notes that if a patient has not achieved at least 5% weight loss after six months at the highest dose they can tolerate, continuing treatment should be reviewed. That criterion applies at every stage, not just at 15mg. You can find fuller context on the maximum dose of tirzepatide page, including what prescribers consider when the ceiling is reached, and our page on the max dosage of Mounjaro explains how that upper limit is applied in practice.

For a sense of how Mounjaro fits into the broader weight-loss treatment landscape, the weight-loss treatment overview sets out the options a prescriber can discuss with you.

When 15mg is not appropriate, and what the prescriber is watching for

Reaching the max dosage of tirzepatide is not the right goal for everyone. Contraindications, existing conditions and tolerability all shape what a prescriber can safely recommend. People with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or certain gastrointestinal conditions will need a careful clinical conversation before any dose increase is considered.

Side effects to flag to your prescriber at any dose include severe or persistent stomach pain that radiates toward the back, this can be a sign of pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines as a known but infrequent serious risk. Dehydration from prolonged vomiting or diarrhoea also warrants prompt contact, as does any allergic reaction. None of this means 15mg is dangerous for most people; it means the schedule should be clinician-led rather than self-directed.

Women taking oral contraceptives should be aware that tirzepatide can reduce pill absorption, particularly in the first four weeks of treatment and for four weeks after each dose increase, an additional contraceptive method is advisable during those windows. The Mounjaro overview page covers safety considerations in more depth.

If you are thinking about starting treatment or have questions about where you are in the titration schedule, checking your eligibility with our prescribers is a sensible first step. Every repeat order at nume is clinically reviewed before dispatch, the dose you are on is never assumed to be the right one to continue without that check.